Faecalibacterium prausnitzii
Faecalibacterium prausnitzii is a butyrate-producing commensal bacterium that is among the most abundant in a healthy human gut and has attracted significant research interest as a potential next-generation probiotic. Multiple reviews and observational studies have examined F. prausnitzii abundance in relation to inflammatory bowel conditions such as Crohn's disease, and animal model work has examined intestinal inflammation and gut barrier function, including in relation to a secreted protein. In vitro studies have characterized its butyrate production, including in the context of cross-feeding with bifidobacteria. Human RCT data on this organism as a direct supplement are limited, and it remains challenging to culture. These are research topics, not findings; the papers do not establish that this strain treats or prevents any condition.
Where it's been studied Tags come from a conservative keyword scan of each paper's title, abstract, and summary. A tag is research coverage, not measured effect. How we classify this →
Share of this strain's 1,078 body-system-tagged papers that concern each system. Research coverage, not measured effect.
Symptoms in the research A tag means the paper's text names the symptom or condition — research coverage, not evidence of benefit. How we classify this →
Share of this strain's 504 symptom-tagged papers that mention each symptom or condition. Research coverage, not evidence of benefit.
+13 more symptoms
Research Study-type filters use AI-classified labels, audited but not guaranteed — check the paper itself before leaning on one. How we classify this →
1279 papers reference this strain in the probiotic database.
Discussion
Be the first to comment.
Sign in to join the discussion.
Citations
Selected papers that name this strain.
-
[1]
Source →Faecalibacterium prausnitzii induziert antiinflammatorische Mononozytenantwort· Zeitschrift für Gastroenterologie · 2026
-
[2]
PMID 42622353 →Preventive effects of Faecalibacterium prausnitzii on chronic alcoholic liver injury and associated alterations in gut microbiota and host phenotypes in mice· Journal of Applied Microbiology · 2026
-
[3]
Source →IDDF2026-ABS-0372 Identification of a highly potent microbial anti-inflammatory molecule (MAM) from faecalibacterium prausnitzii strains· · 2026
-
[4]
PMID 42429614 →Higher abundance of Faecalibacterium prausnitzii in the gut microbiome is associated with a lower risk of sepsis development among 6,372 individuals followed for 20 years· mSystems · 2026
-
[5]
Source →Faecalibacterium prausnitzii in the gut protects against acute lung injury in influenza through butyrate educated reparative CD4+T cells· Microbiome · 2026
-
[6]
Source →IDDF2026-ABS-0190 Phytosphingosine derived from faecalibacterium prausnitzii-derived extracellular vesicles attenuates ulcerative colitis via targeting of LRP6· · 2026
-
[7]
PMID 42307077 →Butyrate‐Producing Bacteria in Intestinal Disease Therapy: Potential and Challenges· Biotechnology Journal · 2026
-
[8]
PMID 42259828 →Faecalibacterium-derived spermidine mediates the amelioration of fatty liver hemorrhagic syndrome by inulin in laying hens· npj Biofilms and Microbiomes · 2026
-
[9]
Source →Comparative Genomic Insights into Pangenome Diversity and Functional Adaptation of Akkermansia and Faecalibacterium as Gut-Associated Next-Generation Probiotics: A Systematic Review· · 2026
-
[10]
PMID 42689867 →Gut microbiota and metabolic alterations in participants with flatulence identify Faecalibacterium prausnitzii as a key microbial target for clinical intervention· Gut Microbes · 2026